The interaction between CD28 on T cells with CD80 (B7-1) and CD86 (B7-2) on APCs is considered to be of critical importance for primary T cell activation both in vivo and in vitro. The relative importance of this co-stimulatory signal in memory T cell activation is, however, less clear, and was therefore studied by in vitro experiments on T cell responses to soluble recall antigens using peripheral blood mononuclear cells or T cell clones. Our data demonstrate that B7-2 represents the major co-stimulatory signal for the activation of resting peripheral blood memory T cells with recall antigens, as evidenced by the effects of anti-B7-1 and anti-B7-2 on T cell proliferation as well as on IL-2 and INF-y production. Since CTLA-4-lg and anti-CD28 Fab fragments had similar inhibitory effects to the combination of anti-B7-1 plus anti-B7-2, the involvement of a third co-stimulatory CD28/CTLA-4 ligand is unlikely. Despite the strong effects of B7-blocking agents, a variable fraction of the memory T cells was resistant to inhibition. Moreover, T cell clones or in vitro preactivated T cells could efficiently be restimulated by soluble antigens on autologous APCs in the absence of B7-1 or B7-2 co-stimulation. These data show that most memory T cells that are freshly isolated from the blood are still dependent on CD28 triggering for their activation. However, recently activated T cells can apparently bypass the requirement for B7 and use other costimulatory signals for reactivation, a finding with important implications for the development of immunosuppressive strategies.
Introduction
Optimal induction of T cell effector functions after TCR recognition of antigen bound to MHC molecules requires costimulatory signals (1) . The interaction of CD28 on T cells with B7 family (B7-1/CD80 and B7-2/CD86) molecules on APCs is now considered as the most important accessory signal (2, 3) . The CD28 molecule is expressed as a homodimer on the majority of T cells. Ligation of CD28 by anti-CD28 mAb, B7-1 or B7-2 co-stimulates T cell proliferation and cytokine production, involving stabilization of mRNA for cytokines and enhancement of cytokine gene transcription (4, 5) . B7-1 and B7-2 are members of the Ig superfamily and are expressed on professional APCs and activated T cells. B7-1 and B7-2 seem to have similar co-stimulatory activities, as evidenced by experiments with B7-1 or B7-2 transfectants (6,7), but both molecules could have different functions since there are differences in their distribution and the kinetics of their expression after cell activation. Resting human B cells are B7-negative, and upon activation B7-2 appears more rapidly than B7-1 (8) . Human peripheral blood monocytes constitutively express B7-2, whereas B7-1 is only expressed on monocytes after activation with IFN-yor GM-CSF (8) (9) (10) . Peripheral blood dendritic cells (DCs) are CD80-negative, and only express CD86 weakly, but both molecules are rapidly induced during culture (11) . DCs generated from CD34 + precursors express CD80 before they express CD86 (12) , and tissue or cultured DCs express both CD80 and CD86 (13) (14) (15) . To date, the role of B7-1/B7-2 has largely been studied with artificial APCs transfected with B7 and/or with a soluble CTLA-4-lg fusion protein that is able to block B7-CD28 interaction. CTLA-4 is a second counter-receptor for both B7-1 and B7-2, and is expressed on activated T cells, functioning as a negative signal receptor (16) . A fusion protein consisting of the extracellular domain of CTLA-4 joined to a human lgG1 binds B7-1 with a 20-fold higher affinity than an analogous CD28-lg fusion protein and blocks interaction of CD28 with its natural ligands (17) . It was found that CTLA-4-lg blocks alloantigen responses in vitro (18) , reduces antibody responses in vivo (19, 20) and prolongs the survival of organ transplants (21, 22) From most studies, it would appear that this co-stimulatory signal is important for primary responses of naive T cells. A large body of evidence supports the concept of B7 costimulation being important for the stimulation of memory T cells, gathered using experiments with T cell clones. One group, using human T cell clones and DR7-B7 transfected APCs has shown that human memory T cell activation does require co-stimulation, and that B7 can provide this signal (23, 24) After separation of T cells on the basis of their expression of CD45RA and CD45RO, using a polyclonal stimulus for T cell activation, we previously found that the requirement for B7 co-stimulation is more stringent for naive than for memory T cells (25) . In a recent paper it was reported that the antigen-presenting function of DCs in secondary in vitro T cell responses to soluble protein antigens can be blocked only partially with anti-B7 reagents (26) In this study we investigated the importance of CD28 triggering and the relative roles of B7-1 and B7-2 for antigenspecific memory T cell activation. This was studied in vitro by addition of blocking reagents, specific for each of the B7 molecules, to cultures of resting, preactivated or cloned T cells in the presence of recall antigens, using autologous APCs [which potentially express multiple co-stimulatory signals (27) ]. The use of recall antigens has the advantage that it automatically selects for memory T cells among a polyclonal T cell population. The issue addressed is of vital importance to the development of immune suppressive treatment with anti-B7 reagents
Methods

Cells and culture media
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood obtained from healthy donors by Ficoll-Hypaque density centrifugation and resuspended in complete medium: RPMI 1640 (Gibco, Paisley, UK) supplemented with 2 mM L-glutamine, streptomycin (100 ng/ml), penicillin (100 U/ml) and 5% heat-inactivated autologous plasma Donors were selected for their known reactivities to the recall antigens used. Enriched monocyte preparations were prepared by rosetting of PBMCs with AET-treated sheep red blood cells and removal of E-rosetting cells on FicollHypaque density gradients followed by cold aggregation of monocytes (28) .
T cell clones
T cell clones specific for the house dust mite Dermatophagoides pteronyssimus (Dp) major allergen Der pi I were generated from the peripheral blood of a non-atopic control donor (PBA1, T h 0) (29) and an atopic donor (JBA2, T h 2) (30). BCT 1.2 (T h 1), a gift from Dr Katarina Hilkens, Academic Medical Center, Amsterdam, was obtained from a non-atopic control donor and is specific for tetanus toxoid (K. Hilkens, unpublished data). The T cell clones were routinely cultured in 24-well plates, in incomplete modified Dulbecco's medium supplemented with 5% human serum, recombinant human IL-2 (10 U/ml) and phytohemagglutinin (PHA) (1 ng/ml), in the presence of a feeder mixture of irradiated PBMCs from two unrelated donors and irradiated cells of the B cell line JY. Fresh feeder cells, PHA and IL-2 were used every 14 days. In each experiment T cell clones were used 10 days after their last stimulation with PHA and IL-2, Under these circumstances background proliferation in the absence of specific antigen was always <1000 c p.m., so these could be considered as resting cells.
mAbs and other reagents mAb B7-24 (anti-CD80) was obtained from a fusion of SP2/ 0 murine myeloma cells with splenocytes from a mouse immunized with Sf9 insect cells expressing the human B7-1 molecule (31, 32) , and was used as purified antibody. mAb IT2.2 (anti-CD86 or anti-B7-2), purified or PE-labelled, was purchased from Pharmingen, San Diego, CA These anti-CD80 and anti-CD86 mAbs have been shown to block the receptor binding of their ligands (32, 33) . Anti-CD28 Fab (clone 28.3) was a gift from Dr D. Olive, INSERM, Marseille, France A cell line secreting human CTLA-4-lg fusion protein was a gift from Dr A. Lanzavecchia, Basel Institute of Immunology, Basel, Switzerland. It was used at a concentration of 5-10 (xg/ml, which in a preliminary experiment was shown to completely block co-stimulation with B7-transfected cells. Tuberculin was purchased from Statens Serum Institut, Copenhagen, Denmark. Influenza virus antigen was from Solvay-Duphar (Weest, The Netherlands) and varicella and mumps antigens were from Hoechst (Marburg, Germany). Tetanus toxoid was from RIVM (Bilthoven, The Netherlands) and Candida albicans antigen from ARTU (Lelystad, The Netherlands). Protein extracts of Dp were prepared from lyophilized mite cultures (kindly provided by HAL, Haarlem, The Netherlands) After dialysis with PBS, the HAL Dp extract used in this study contained 38.3 x 10 6 U/ml Der p 2, as compared with the International Reference Preparation for Dp extracts (NIBSC 82/518) (34) Recombinant IFN-y was purchased from Boehringer (Mannheim, Germany).
Proliferation assay
PBMCs (1 x 10 6 /ml) were cultured with tuberculin (20 U/ml), influenza virus antigen (1/200), varicella antigen (100 mU/ml), mumps antigen (1/2000), tetanus toxoid (1 5 Lf/ml) or Candida albicans (10 ng/ml) in 200 |il of complete culture medium in a 96-well round-bottomed culture microplate. For blocking studies, mAbs anti-B7-1 and anti-B7-2 (at different concentra- 
Flow cytometnc analysis
Isolated PBMCs (0.5 x 10 6 c/ml) were cultured in medium alone, or incubated with tuberculin (20 U/ml) or INF-y (1000 U/ml) for 24, 48 or 72 h Fresh and cultured PBMCs were stained with anti-B7-1 mAb plus goat anti-mouse IgG-FITC, or with anti-B7-2-PE for 30 min. After two washes with PBS, cells were fixed with 1 % paraformaldehyde and analyzed on a FACsort (Lysys II software) with a scatter gate on monocytes
Cytokme production
PBMCs (1 x 10 6 c/ml) were cultured with tuberculin (20 U/ ml) or varicella antigen (100 mU/ml) in the presence or absence of anti-B7-1/anti-B7-2 mAbs and CTLA-4-lg as described above For IL-2 production, anti-Tac mAb (2 (ig/ ml) was added to the cultures in order to block IL-2 consumption (35) . Supernatants were collected after 48-72 h of incubation.
Cytokme assays
IL-2 was assayed by its ability to induce growth of mouse CTLL cells Concentrations were expressed in mU/ml by comparison with the activity of an IL-2 reference preparation (35) . detected by ELISA using a pair of mAbs (anti-IL-4 SL and anti-IFN-y SL from Medgenix Diagnostics, Fleurus, Belgium; anti-IL-10 from Pharmingen, San Diego, CA) Plastic plates with 96 wells (Nunc-lmmuno plate) were coated overnight with anti-cytokine-capture mAb. Culture supernatants or standard solutions were added with the respective biotinylated anticytokine-detecting mAb. The plates were incubated and washed, and subsequently peroxidase-conjugated streptavidin and tetramethylbenzidine chromogen solution were added Optical density readings were done at 450 nm on an ELISA reader The result was calculated by comparison with a standard of recombinant cytokines
Results
Antigen-induced T cell proliferation is highly dependent on B7-2, but not on B7-1 molecules
PBMCs were cultured with several soluble recall antigens (tuberculin and antigens from influenza, varicella and mumps viruses) in the presence of anti-B7-1 or anti-B7-2 mAbs, or a combination of both. After 6 days the proliferate response of T cells was determined by measuring 3 [H]thymidine incorporation. Donors were selected on the basis of their known reactivities to recall antigens. As shown in Fig 1, anti-B7-1 mAb either failed to inhibit or only slightly inhibited the proliferation. In contrast, proliferation was strongly inhibited by anti-B7-2 mAb (70% ± 20, n = 5). The combination of anti-B7-2 and anti-B7-1 resulted in a stronger inhibition than anti-B7-2 alone The maximal inhibitory rates for each antigen were quite variable from donor to donor, e.g. 50-90% for influenza virus antigen stimulation When PBMCs were cultured with antigen in the presence of a constant amount (5 ng/ml) of anti-B7-1 mAb, which by itself had no effect, addition of anti-B7-2 mAb inhibited T cell proliferation in a dose-dependent manner, as illustrated for tuberculin stimulation in Fig. 2(A) . At a dosage as low as 0.5 ng/ml, anti-B7-2 still strongly reduced the proliferation On the other hand, in the presence of a constant amount of anti-B7-2 mAb (2 ng/ ml), addition of anti-B7-1 also resulted in concentrationdependent inhibition of T cell proliferation (Fig 2B) These results suggest that B7-2 rather than B7-1 provides the dominant co-stimulatory signal for antigen-specific activation of resting memory T cells in PBMC cultures The contribution of B7-1 was apparent only under culture conditions where B7-2 had first been blocked To study B7-1 and B7-2 expression on monocytes (which are potentially the most important APCs for soluble antigens in PBMC cultures), PBMCs were cultured in medium alone, or with tuberculin (20 U/ml) or IFN-y (1000 U/ml) for 24, 48 or 72 h Using freshly isolated PBMCs, we confirmed that B7-2 was expressed on fresh monocytes whereas staining for B7-1 was negative, as previously reported (9, 26, 33) Similar results were obtained when fresh whole blood samples collected on EDTA were stained with those mAbs and then analysed on the FACS after lysis of the red blood cells (n = 10). This method completely avoids monocyte activation as a result of the isolation procedures. Incubation of PBMCs in medium alone resulted in up-regulation of both B7-1 and B7-2 expression on monocytes, with maximal expression after 24-48 h and a decline thereafter (not shown). Addition of tuberculin (20 U/ml) to the cultures did not alter B7-1 or B7-2 expression compared with addition of medium alone In contrast, INF-y up-regulated both B7-1 and B7-2 expression, and prevented the decline of B7-1 and B7-2 expression on cultured monocytes. Up-regulation of B7-1 on monocytes cultured in INF-y has also been shown by Freedman et al (9) .
CTLA-4-lg or anti-CD28 Fab inhibits antigen-specific T cell activation to the same extent as a combination of anti-B7-1 and anti-B7-2 mAbs
The inhibition of T cell proliferation in response to stimulation by soluble antigens, by the combination of anti-B7-1 and anti-B7-2, was often not complete A recent report suggests that activated B cells express a third stimulatory ligand for the CD28 counter-receptor (37) . To study whether a third CD28 ligand might be implicated, we cultured PBMCs with antigens 
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(tuberculin, influenza virus, varicella and mumps virus) in the presence of CTLA-4-lg or the combination of anti-B7-1 and anti-B7-2 mAbs. As shown in Fig 3(A) , CTLA-4-lg had an inhibitory effect comparable with the combination of anti-B7-1 and anti-B7-2 mAbs A third CD28 ligand might fail to bind CTLA-4, as suggested by the work of Nickoloff et al. (38) . However, similar inhibition of T cell proliferation in response to tetanus toxoid or Candida was also observed by anti-CD28 Fab and by the combination of anti-B7-1 and anti-B7-2 mAbs (Fig 3B) . Our data thus fail to provide evidence for the existence of a third co-stimulatory CTLA-4/CD28 ligand other than B7-1 and B7-2. In view of the evidence that T cell activation always requires a co-stimulatory signal (1), the resistance of a subpopulation of peripheral memory T cells to inhibition by B7-blocking agents seems likely to depend on other co-stimulatory signals, as was suggested by Johnson and Jenkins (27) .
Effects of anti-B7-1/anti-B7-2 mAbs on antigen-induced cytokme production
Next we tested whether the production of cytokines in cultures of PBMCs with soluble antigens can be inhibited by addition of anti-B7-1/anti-B7-2 mAbs or CTLA-4-lg. PMBCs were stimulated with tuberculin or varicella antigen in either the presence or absence of these blocking agents Both IL-2 and INF-y were produced in these cultures, but we failed to detect IL-4 (<30 pg/ml) or IL-10 (<100 pg/ml). It was observed that anti-B7-1 partially inhibited the production of IL-2 and IFN-y, and that anti-B7-2 reduced cytokine release more than anti-B7-1 did. Again, the combination of anti-B7-2 plus anti-B7-1 mAbs had a stronger inhibitory effect on IL-2 and IFN-y production than did either mAb alone, and CTLA-4-lg similarly inhibited the release of these two cytokines (Table 1) The data on cytokine production thus correlated with the effects of anti-B7-1, anti-B7-2 and CTLA-4-lg on T cell proliferation. It seems that blocking B7-1 affects IFN-y production more strongly than it affects proliferation, but the effect of anti-B7-2 on both aspects of T cell activity was much more dramatic. Our failure to induce IL-4 production in PBMC cultures did not allow us to study the potentially different effects of B7-1 and B7-2 costimulation on T h 1 and T h 2 cells respectively (39, 40) . On the other hand, our data clearly show that B7-2 contributes in a major way to IFN-y production.
Activation of pre-activated T cells and T cell clones is less dependent on B7 co-stimulation
Residual T cell activation, despite the addition of a combination of anti-B7-1 and anti-B7-2, could result from CD28-independent activation of a subpopulation of T cells. We hypothesized that memory T cells which had recently encountered antigens could bypass the need for co-stimulation through CD28. To test this hypothesis, two approaches were used. First, PBMCs were stimulated with antigens (tuberculin, Candida or mumps virus); the cells then rested for 2 days, and restimulated with the original antigens and fresh autologous monocytes in either the presence or absence of CTLA-4-lg. These T cells, as expected, required antigen to induce proliferation However, it was observed that CTLA-4-lg did not block or only partially blocked proliferation of such preactivated T cells, in contrast to its potent inhibitory effect on proliferation of fresh T cells (Table 2 ). In a second approach, we stimulated three different resting T cell clones with T h 0 (Dp-specific), T h 1 (tetanus toxoid-specific) and T h 2 (Dpspecific) phenotypes with antigens and autologous irradiated PBMCs as APCs. Supematants from these experiments were also tested for IL-2, IFN-y, IL-4 and IL-5 production. Again, addition of CTLA-4-lg did not inhibit or only slightly inhibited proliferation (Fig 4A) and cytokine production (Fig. 4B) . These data indicate that B7 co-stimulation is not crucial for activation of pre-activated T cells and T cell clones. It could be deduced from these data that the efficacy of anti-B7 reagents to block T cell activation in vivo will probably depend on the time lag since the last antigen encounter.
Discussion
In this study we demonstrate that B7-2 and, to a lesser degree, B7-1 both contribute to induction of proliferation Table 1 . Effects of anti-B-7-1/anti-B-7-2 mAbs and CTLA-4-lg on IL-2 and IFN-y production 95  133  33  32  26   1384  811  315  275  286   963  1035  293  93  128   2158  999  96  <20  <20   2269  866  1748  584  538   2068  860  450  440  398   2700  612  432  379  328 a PBMCs (1X10 6 c/ml) were cultured with tuberculin (20 U/ml) or varicella virus antigen (100 mU/ml) in the presence or absence Of anti-B-7-1, anti B-7-2 and CTLA-4-lg (5 (ig/ml for each) for 48 (donor 1) or 72 h (donor 2). Supematants were analysed by bioassay for IL-2 and by ELISA for IFN-y.
at Pennsylvania State University on February 23, 2013 http://intimm.oxfordjournals.org/ Downloaded from of, and cytokine production (IL-2 and IFN-y) by, antigenstimulated resting memory T cells from peripheral blood. The effect of anti-B7-1 could be clearly demonstrated under conditions where B7-2 was blocked. CTLA-4-lg or anti-CD28 Fab had a similar inhibitory effect to the combination of anti-B7-2 and anti-B7-1 on antigen-specific proliferation, making the involvement of a third co-stimulatory CD28/CTLA-4 ligand unlikely. The availability of B7-2 during the early part of the stimulation process and the strong expression of B7-2 on monocytes are consistent with the major role of B7-2 when monocytes are the APCs. However, we cannot completely exclude the possibility that DCs contribute to the antigen presentation Peripheral blood DCs, similar to monocytes, are CD80-negative and only weakly CD86-positive (11) Both molecules are rapidly induced during culture, with CD86 being clearly positive after 8 h, and CD80 after 24 h. These kinetics thus seem to be similar to that of B7 expression on monocytes. It is therefore remarkable that B7-1 can provide a co-stimulatory signal under conditions where B7-2 is blocked by mAb, even though it is apparently not available at initiation of the culture. Induction during the first 24 h of culture is apparently sufficient for efficient co-stimulation. These data do not exclude the possibility that in certain in vivo circumstances B7-1 is of equal or dominant importance. Differences in the availability of B7-1 and B7-2 for co-stimulation under different conditions of antigen presentation might determine their relative importance in vivo. The fact that tissue DCs express both B7-1 and B7-2 (13-15) would also support the importance of both B7 family members.
Some recent data have suggested that B7-2 is more important for T h 2 cell responses (39, 40) . In our experiments we were unable to induce IL-4 production, although B7-2 was the main co-stimulatory signal. On the other hand, it can be concluded that B7-2 is also a good inducer of the T h 1 cytokine IFN-y. An experimental system with freshly isolated T cells from atopic donors and allergen will probably be required to address antigen-specific T h 1/T h 2 balances with B7-1/B7-2 co-stimulation. T cell clones seem to be less suitable for this purpose, since neither IL-4 nor IL-5 production from T^O clones could be inhibited with CTLA-4-lg. Peripheral blood T cells, most of which have not seen antigens for a long time, represent a source of memory T cells. They are apparently strongly dependent on B7 family members for co-stimulation as shown in this study and, as a consequence, they apparently cannot use the other costimulatory signals from monocytes such as LFA-3 or ICAM-3. However, we repeatedly found that a subset of T cells did not require B7 co-stimulation. Moreover, pre-activated T cells and T cell clones could also be stimulated by antigens in the absence of B7 co-stimulation These data suggest that not all memory T cells are dependent on CD28 co-stimulation. In a recent paper Fagnoni et al. (26) have in fact used isolated DCs to present soluble antigens to freshly isolated T cells These authors could block T cell responses to soluble antigens by up to -80%, using a combination of anti-B7-1 and anti-B7-2 Anti-B7-2 had more dramatic effects than anti-B7-1. These data are in accordance with our findings and also indicate that a subset of memory cells is independent from B7 co-stimulation. Most interestingly, the authors were able to induce primary responses to soluble antigens in vitro when DCs were used as APCs, but not when monocytes were used. These primary responses seemed more sensitive to inhibition with anti-B7 than secondary responses. The possibility of inducing primary responses to antigens with DCs as APCs, together with our finding that most donors tested were in fact negative for tuberculin reactivity, strongly argues against a major role of DCs in cultures of PBMCs.
Independence of T cell clones from B7 co-stimulation is only at first sight in contradiction with other data from the literature, showing that alloantigen-specific human T cell clones or tetanus toxoid-specific T cell clones use B7-1 as a co-stimulatory signal (23, 24) . In this situation, B7 was the only accessory signal presented on DR-7/B7-transfected cells. ICAM-1 could not substitute for B7. The T cell clones in those studies clearly required co-stimulation, but the question of whether co-stimulatory signals other than B7 would be effective has not yet been addressed in detail. Our data do, however, suggest that this will be the case. If T cells which have recently encountered antigens under stimulating conditions can indeed bypass the requirement for B7 co-stimulation, this also explains why they are not strictly dependent any more on antigen presentation by professional APCs. For example, resting B cells which have been shown to be defective in CD28-dependent co-stimulation of naive CD4 T cells (41) could become efficient APCs for recently activated memory T cells (42) without B7 co-stimulation.
Our findings have a number of important implications for therapeutic approaches. First, it is clear that inhibition of T cell responses to soluble antigens will require the blocking of both B7-2 and B7-1 to be effective. More important, it is unlikely that ongoing T cell responses will be susceptible to inhibition by anti-B7 reagents, for example in autoimmune diseases. The failure to block established experimental allergic encephalitis under conditions of adoptive transfer supports this conclusion (43) . In these cases, a search for 
